Intravenous immunoglobulin‐associated cranial pachymeningitis

. To date, intravenous immunoglobulin (IvIg) has more often been considered as a safe medication. However, with the wider use of IvIg, severe side effects have also been reported to occur in IvIg‐treated patients, notably aseptic meningitis. Other neurological complications have more rarely been des...

Full description

Saved in:
Bibliographic Details
Published in:Journal of internal medicine 2006-08, Vol.260 (2), p.164-167
Main Authors: MARIE, I., HERVÉ, F., LAHAXE, L., ROBADAY, S., GERARDIN, E., LEVESQUE, H.
Format: Article
Language:English
Subjects:
acute encephalopathy
Adult
aseptic meningitis
Bioengineering
Biological and medical sciences
cranial pachymeningitis
Dura Mater
Dura Mater - pathology
Gadolinium
General aspects
Humans
Immunoglobulins, Intravenous
Immunoglobulins, Intravenous - adverse effects
intravenous immunoglobulin
Kidney Diseases
Kidney Diseases - diagnosis
Kidney Diseases - therapy
Life Sciences
Magnetic Resonance Imaging
Male
Medical sciences
Meningitis, Aseptic
Meningitis, Aseptic - diagnosis
Meningitis, Aseptic - etiology
Neurology
Nuclear medicine
Polyarteritis Nodosa
Polyarteritis Nodosa - diagnosis
Polyarteritis Nodosa - therapy
Radioisotopes
stroke
Tomography, X-Ray Computed
Vascular diseases and vascular malformations of the nervous system
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:. To date, intravenous immunoglobulin (IvIg) has more often been considered as a safe medication. However, with the wider use of IvIg, severe side effects have also been reported to occur in IvIg‐treated patients, notably aseptic meningitis. Other neurological complications have more rarely been described in patients receiving IvIg therapy, e.g. stroke or acute encephalopathy. We recently observed a case which is of particular interest, as the patient with steroid‐refractory polyarteritis nodosa developed cranial pachymeningitis related to IvIg therapy. To our knowledge, this is the first reported case of cranial pachymeningitis complicating IvIg therapy. Our findings emphasize the importance of recognizing IvIg‐related neurological complications in IvIg‐treated patients. As cranial pachymeningitis is a fibrosing process, both recognition and management at an early stage are required to prevent definite neurological impairment in patients.
ISSN:0954-6820
1365-2796
DOI:10.1111/j.1365-2796.2006.01676.x